Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bempedoic acid/ezetimibe - Esperion Therapeutics

Drug Profile

Bempedoic acid/ezetimibe - Esperion Therapeutics

Alternative Names: ETC-1002/ezetimibe; Ezetimibe/bempedoic acid; Ezetimibe/ETC-1002

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics; Azetidines; Dicarboxylic acids; Fatty acids; Fluorobenzenes; Propanols; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Cholesterol absorption inhibitors; Cholesterol synthesis inhibitors; NPC1L1 protein inhibitors; Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hypercholesterolaemia

Most Recent Events

  • 30 Aug 2019 Efficacy and adverse events data from a phase II trial in Type 2 diabetes mellitus released by Daiichi Sankyo
  • 18 Jun 2019 Esperion Therapeutics completes a phase II trial for Type 2 diabetes mellitus in USA (PO, Tablet) (NCT03531905)
  • 05 May 2019 The US FDA accepts NDA for bempedoic acid/ezetimibe for Hypercholesterolemia for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top